Advertisement

Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. The WSJ explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.

Advertisement
Advertisement